tiprankstipranks
Advertisement
Advertisement

EXEL Stock Latest News

Exelixis announces results from subgroup analysis of Phase 3 Cabinet trial
The FlyExelixis announces results from subgroup analysis of Phase 3 Cabinet trial
4d ago
EXEL
Exelixis Shareholders Approve Equity Plan and Board Slate
PremiumCompany Announcements
Exelixis Shareholders Approve Equity Plan and Board Slate
6d ago
8K
EXEL
Exelixis Earnings Call Highlights Strong Cabo Momentum
PremiumCompany Announcements
Exelixis Earnings Call Highlights Strong Cabo Momentum
16d ago
EXEL
Exelixis announces clinical development collaboration with Merck
PremiumThe Fly
Exelixis announces clinical development collaboration with Merck
16d ago
MRK
EXEL
Exelixis Advances Zanzalintinib Into Phase 2 Meningioma Trial, Signaling Pipeline Expansion
PremiumCompany Announcements
Exelixis Advances Zanzalintinib Into Phase 2 Meningioma Trial, Signaling Pipeline Expansion
17d ago
EXEL
Exelixis price target raised to $56 from $54 at H.C. Wainwright
PremiumThe FlyExelixis price target raised to $56 from $54 at H.C. Wainwright
28d ago
EXEL
Exelixis price target raised to $50 from $49 at Morgan Stanley
Premium
The Fly
Exelixis price target raised to $50 from $49 at Morgan Stanley
29d ago
EXEL
Exelixis price target raised to $47 from $44 at Stifel
Premium
The Fly
Exelixis price target raised to $47 from $44 at Stifel
29d ago
EXEL
Exelixis price target raised to $55 from $51 at TD Cowen
PremiumThe Fly
Exelixis price target raised to $55 from $51 at TD Cowen
29d ago
EXEL
Exelixis Earnings Call Highlights Growth And ZANZA Risks
PremiumCompany Announcements
Exelixis Earnings Call Highlights Growth And ZANZA Risks
29d ago
EXEL
Exelixis Kept at Hold as Cabo Momentum Offsets Pipeline Uncertainty; Price Target Raised from $49 to $50
PremiumRatings
Exelixis Kept at Hold as Cabo Momentum Offsets Pipeline Uncertainty; Price Target Raised from $49 to $50
30d ago
EXEL
Exelixis Price Target Raised to $55 on Cabo Strength, Buyback-Driven EPS Growth, and Zanzalintinib Upside Optionality
PremiumRatings
Exelixis Price Target Raised to $55 on Cabo Strength, Buyback-Driven EPS Growth, and Zanzalintinib Upside Optionality
30d ago
EXEL
Analyst Reiterates Buy on Exelixis, Citing STELLAR-304 Momentum, Cabometyx Durability, and Share Repurchases
PremiumRatingsAnalyst Reiterates Buy on Exelixis, Citing STELLAR-304 Momentum, Cabometyx Durability, and Share Repurchases
30d ago
EXEL
Exelixis Posts Strong Q1 Results, Expands Share Buybacks
Premium
Company Announcements
Exelixis Posts Strong Q1 Results, Expands Share Buybacks
1M ago
8K
EXEL
EXEL Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
EXEL Earnings this Week: How Will it Perform?
1M ago
EXEL
Exelixis and Merck Advance Key Phase 3 Kidney Cancer Trial, Setting Up a New Catalyst for EXEL
PremiumCompany Announcements
Exelixis and Merck Advance Key Phase 3 Kidney Cancer Trial, Setting Up a New Catalyst for EXEL
1M ago
EXEL
Exelixis price target raised to $45 from $44 at Barclays
PremiumThe Fly
Exelixis price target raised to $45 from $44 at Barclays
2M ago
EXEL
Recursion Pharmaceuticals announces Vicki Goodman as chief medical officer
PremiumThe Fly
Recursion Pharmaceuticals announces Vicki Goodman as chief medical officer
2M ago
EXEL
RXRX
Exelixis price target lowered to $43 from $46 at RBC Capital
PremiumThe Fly
Exelixis price target lowered to $43 from $46 at RBC Capital
3M ago
MRK
EXEL
Hold Rating on Exelixis Amid Emerging Belzutifan Competition and Uncertain Cabo Revenue Visibility
PremiumRatingsHold Rating on Exelixis Amid Emerging Belzutifan Competition and Uncertain Cabo Revenue Visibility
3M ago
EXEL
Exelixis: Welireg Competition Tempers RCC Upside but Embedded Cabozantinib Franchise Supports Hold Rating
Premium
Ratings
Exelixis: Welireg Competition Tempers RCC Upside but Embedded Cabozantinib Franchise Supports Hold Rating
3M ago
EXEL
Crocs, Linde, Zillow, Exelixis, Qorvo: Insider Cash-Outs
Premium
Weekend Updates
Crocs, Linde, Zillow, Exelixis, Qorvo: Insider Cash-Outs
3M ago
Z
LIN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >